Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism

Am J Reprod Immunol. 2011 Dec;66(6):527-33. doi: 10.1111/j.1600-0897.2011.01059.x. Epub 2011 Jul 31.

Abstract

Problem: Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder. This study was to evaluate whether insulin receptor substrate (IRS)-2 Gly1057Asp polymorphism influences chronic inflammatory parameters in Taiwanese patients with PCOS.

Method of study: DNA was extracted from whole blood samples for genotyping and detection of IRS-2 Gly1057Asp polymorphism in 129 PCOS women and 109 control women. Ninety-seven PCOS women accepted metformin treatment for 3 months, and low-grade chronic inflammatory markers were assessed.

Results: The levels of IL-6 were significantly elevated in PCOS women compared with normal women. Among allelic variant of IRS-2, concentrations of IL-6 were greater in IRS-2 homozygous Asp population. Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant.

Conclusion: The results showed that IL-6 may be an early low-grade chronic inflammatory marker among PCOS patients with IRS-2 polymorphism in Taiwanese population. This pharmacologic study in IRS-2 polymorphism may provide more information for preventing long-term complications in PCOS.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Case-Control Studies
  • Female
  • Homozygote
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Inflammation / immunology
  • Inflammation Mediators / blood
  • Insulin Receptor Substrate Proteins / genetics*
  • Interleukin-6 / blood*
  • Metformin / therapeutic use
  • Middle Aged
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / epidemiology
  • Polycystic Ovary Syndrome / genetics*
  • Polycystic Ovary Syndrome / immunology*
  • Polymorphism, Genetic*
  • Taiwan / epidemiology
  • Treatment Outcome
  • Young Adult

Substances

  • Hypoglycemic Agents
  • Inflammation Mediators
  • Insulin Receptor Substrate Proteins
  • Interleukin-6
  • Metformin